Seroprevalence of Hepatitis E in Hemodialysis Patients in Turkey

K. Kuddusi, Cengiz E. Esin, Özyiğitan A.M. Arif Mansur, Coşar M. Murat Günaydın

Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey

Prof. Kuddusi Cengiz, MD, Department of Nephrology, Ondokuz Mayıs University School of Medicine, TR-55139 Kurupelit, Samsun (Turkey)

Dear Sir,

Hepatitis E virus (HEV) and hepatitis C virus (HCV) seem to be the major causes of what was previously known as nonA, nonB hepatitis [1, 2]. HEV is mainly transmitted by the fecal-oral route and HCV by transfusion of blood products [3]. While chronic disease is common in HCV infection, HEV causes epidemic and sporadic hepatitis without the development of chronic liver disease. Cases of hepatitis E seem to occur in many developing countries. Possibly, HEV causes sporadic and silent cases of hepatitis E in industrialized countries. In this study, we investigated the prevalence of HEV antibodies in 72 patients with end-stage chronic renal failure on a maintenance hemodialysis program.

These patients (30 women and 42 men, mean age 45.5 ± 1.8 years, range 17-70) were screened for hepatitis C virus antibody by third-generation enzyme-linked immunosorbent assay (micro-ELISA) (Organon Technica) and hepatitis E virus by macro-ELISA (Abbott). Their renal failure was due to chronic glomerulonephritis (25%), diabetes (19.5%), pyelonephritis (10%), amyloidosis (14%), polycystic kidney disease (12.5%) and other etiologies (19%). The mean duration of time on hemodialysis was 4.7 ± 0.4 years (range 1-16). None of them had a history of acute hepatitis after the hemodialysis program. Their serum alanine aminotransferase levels were less than 1.5 times the upper normal limit (40 U/l). The control group consisted of 54 healthy volunteers (38 women and 16 men, mean age 46.5 ± 0.5 years, range 22-74). None of the healthy subjects showed HCV antibody and hepatitis B surface antigen. Thirty-five of 72 patients (48.6%) were anti-HCV-positive and 12 of 72 patients (16.7%) were Hbs Ag-positive.

For the detection of IgG HEV antibodies, an ELISA test (Abbott, rDNA-antigen) was used. Ten of 72 patients (13.9%) were found to have positive IgG antibodies. This frequency was 5.5% in the control group. Among our HEV antibody-positive patients, 7 of 10 (70%) were also anti-HCV-positive and 3 of 10 (30%) were Hbs Ag-positive (2 patients were anti-HCV, anti-HEV IgG and Hbs Ag-positive). The prevalence of HEV antibody in patients on a maintenance hemodialysis program was higher than the control group (odds ratio 2.63; \( p < 0.01 \)). The frequency in the control group was similar to the frequency of 5.9% reported in the Turkish population [4]. Our results in hemodialysis patients were similar to the 10.8% prevalence reported in 147 French hemodialysis patients [5].
Our results suggest that fecal-oral transmission may not be the only route of transmission of HEV. HEV was shown in the serum [6], and virus transmission in these patients may be related to previous blood transmission or directly to hemodialysis facilities, similar to HCV [7]. The strong correlation between HEV and HCV antibodies positivity may also support this possibility. HEV is more prevalent in Turkey compared to the 3% prevalence in industrialized countries [8], and it may be useful to screen donor blood and hemodialysis patients for HEV antibodies. Further studies in larger patient populations will clarify the issue.

References